Hairy Cell Leukemia Patients Have a Normal Life Expectancy—A 35-Year Single-Center Experience and Comparison with the General Population
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
3.1. Treatment with Interferon-α
3.2. Treatment with Purine Analogues +/− Rituximab
3.3. Comparison of Purine Analogues and Interferon-α
3.4. Comparison with the Austrian General Population
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Campo, E.; Swerdlow, S.H.; Harris, N.L.; Pileri, S.; Stein, H.; Jaffe, E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011, 117, 5019–5032. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bouroncle, B.A.; Wiseman, B.K.; Doan, C.A. Leukemic reticuloendotheliosis. Blood 1958, 13, 609–630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saven, A.; Burian, C.; Koziol, J.A.; Piro, L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998, 92, 1918–1926. [Google Scholar] [CrossRef] [PubMed]
- Chadha, P.; Rademaker, A.W.; Mendiratta, P.; Kim, B.; Evanchuk, D.M.; Hakimian, D.; Peterson, L.C.; Tallman, M.S. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Long-term follow-up of the Northwestern University experience. Blood 2005, 106, 241–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Else, M.; Dearden, C.E.; Matutes, E.; Garcia-Talavera, J.; Rohatiner, A.Z.; Johnson, S.A.; O’Connor, N.T.; Haynes, A.; Osuji, N.; Forconi, F.; et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br. J. Haematol. 2009, 145, 733–740. [Google Scholar] [CrossRef]
- Paillassa, J.; Cornet, E.; Noel, S.; Tomowiak, C.; Lepretre, S.; Vaudaux, S.; Dupuis, J.; Devidas, A.; Joly, B.; Petitdidier-Lionnet, C.; et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020, 10, 62. [Google Scholar] [CrossRef]
- Else, M.; Dearden, C.E.; Catovsky, D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract. Res. Clin. Haematol. 2015, 28, 217–229. [Google Scholar] [CrossRef] [Green Version]
- Bohn, J.P.; Willenbacher, E.; Steurer, M. Obinutuzumab in multidrug-resistant hairy cell leukemia. Ann. Hematol. 2016, 95, 351–352. [Google Scholar] [CrossRef]
- Bohn, J.P.; Wanner, D.; Steurer, M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk. Lymphoma 2017, 58, 1224–1226. [Google Scholar] [CrossRef]
- Bohn, J.P.; Pircher, A.; Wanner, D.; Vill, D.; Foeger, B.; Wolf, D.; Steurer, M. Low-dose vemurafenib in hairy cell leukemia patients with active infection. Am. J. Hematol. 2019, 94, E180–E182. [Google Scholar] [CrossRef] [Green Version]
- Bohn, J.P.; Gastl, G.; Steurer, M. Long-term treatment of hairy cell leukemia with interferon-α: Still a viable therapeutic option. Memo 2016, 9, 63–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Assanto, G.M.; Riemma, C.; Malaspina, F.; Perrone, S.; De Luca, M.L.; Pucciarini, A.; Annechini, G.; D’Elia, G.M.; Martelli, M.; Foà, R.; et al. The current role of interferon in hairy cell leukaemia: Clinical and molecular aspects. Br. J. Haematol. 2021, 194, 78–82. [Google Scholar] [CrossRef]
- Belani, R.; Saven, A. Cladribine in hairy cell leukemia. Hematol. Oncol. Clin. North Am. 2006, 20, 1109–1123. [Google Scholar] [CrossRef] [PubMed]
- Robak, T.; Jamroziak, K.; Gora-Tybor, J.; Blonski, J.Z.; Kasznicki, M.; Dwilewicz-Trojaczek, J.; Wiater, E.; Zdunczyk, A.; Dybowicz, J.; Dmoszynska, A.; et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007, 109, 3672–3675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zenhäusern, R.; Schmitz, S.F.; Solenthaler, M.; Heim, D.; Meyer-Monard, S.; Hess, U.; Leoncini, L.; Bargetzi, M.; Rufener, B.; Tobler, A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: A multicenter phase III trial (SAKK 32/98). Leuk. Lymphoma 2009, 50, 1501–1511. [Google Scholar] [CrossRef] [PubMed]
- Saven, A.; Piro, L. Newer purine analogues for the treatment of hairy-cell leukemia. N. Engl. J. Med. 1994, 330, 691–697. [Google Scholar] [CrossRef] [PubMed]
- Tadmor, T.; Levy, I.; Herishanu, Y.; Goldschmidt, N.; Bairey, O.; Yuklea, M.; Shvidel, L.; Fineman, R.; Aviv, A.; Ruchlemer, R.; et al. Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia. Leuk. Res. 2019, 82, 24–28. [Google Scholar] [CrossRef]
- Zinzani, P.L.; Stefoni, V.; Broccoli, A.; Pellegrini, C.; Gandolfi, L.; Casadei, B.; Maglie, R.; Pileri, S.; Argnani, L. Is it really possible to cure hairy cell leukemia patients only with frontline therapy? Ann. Hematol. 2014, 93, 1565–1569. [Google Scholar] [CrossRef]
- Sigal, D.S.; Sharpe, R.; Burian, C.; Saven, A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010, 115, 1893–1896. [Google Scholar] [CrossRef] [Green Version]
- López Rubio, M.; Da Silva, C.; Loscertales, J.; Seri, C.; Baltasar, P.; Colado, E.; Pérez Fernández, I.; Osma, M.; Gomis, F.; González, M.; et al. Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk. Lymphoma 2014, 55, 1007–1012. [Google Scholar] [CrossRef]
- Troussard, X.; Maître, E.; Cornet, E. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am. J. Hematol. 2022, 97, 226–236. [Google Scholar] [CrossRef] [PubMed]
- Garnache Ottou, F.; Chandesris, M.O.; Lhermitte, L.; Callens, C.; Beldjord, K.; Garrido, M.; Bedin, A.S.; Brouzes, C.; Villemant, S.; Rubio, M.T.; et al. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients. Br. J. Haematol. 2014, 166, 50–59. [Google Scholar] [CrossRef] [PubMed]
- Chihara, D.; Arons, E.; Stetler-Stevenson, M.; Yuan, C.M.; Wang, H.W.; Zhou, H.; Raffeld, M.; Xi, L.; Steinberg, S.M.; Feurtado, J.; et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J. Clin. Oncol. 2020, 38, 1527–1538. [Google Scholar] [CrossRef] [PubMed]
- Grever, M.R.; Abdel-Wahab, O.; Andritsos, L.A.; Banerji, V.; Barrientos, J.; Blachly, J.S.; Call, T.G.; Catovsky, D.; Dearden, C.; Demeter, J.; et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017, 129, 553–560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dinmohamed, A.G.; Posthuma, E.F.M.; Visser, O.; Kater, A.P.; Raymakers, R.A.P.; Doorduijn, J.K. Relative survival reaches a plateau in hairy cell leukemia: A population-based analysis in The Netherlands. Blood 2018, 131, 1380–1383. [Google Scholar] [CrossRef]
- Tiacci, E.; Park, J.H.; De Carolis, L.; Chung, S.S.; Broccoli, A.; Scott, S.; Zaja, F.; Devlin, S.; Pulsoni, A.; Chung, Y.R.; et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N. Engl. J. Med. 2015, 373, 1733–1747. [Google Scholar] [CrossRef]
- Tiacci, E.; De Carolis, L.; Simonetti, E.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P.L.; et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N. Engl. J. Med. 2021, 384, 1810–1823. [Google Scholar] [CrossRef]
- Kreitman, R.J.; Moreau, P.; Hutchings, M.; Gazzah, A.; Blay, J.-Y.; Wainberg, Z.A.; Stein, A.; Dietrich, S.; de Jonge, M.J.A.; Willenbacher, W.; et al. Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). Blood 2018, 132, 391. [Google Scholar] [CrossRef]
- Park, J.H.; Shukla, M.; Salcedo, J.M.; Vemuri, S.; Kinoshita, J.C.; Smith, M.D.; Winer, E.S.; Abdel-Wahab, O.; Tallman, M.S. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2019, 134, 3998. [Google Scholar] [CrossRef]
Median Age at Diagnosis, Years (Range) | 54 (25–84) |
---|---|
Females (%) | 14 (17) |
Follow-up (months), median (range) | 170 (1–498) |
Splenomegaly, n (%) | 55 (66) |
Longitudinal diameter in ultrasound, cm (range) | 16 (14–30) |
Neutrophil count (×109/L), median (range) | 0.8 (0.1–1.4) (n = 42) |
Hemoglobin (g/L), median (range) | 119.5 (54–170) |
Platelet count (×109/L), median (range) | 79 (19–438) |
Any cytopenia, n (%) | 78 (94%) |
BRAFV600 mutation verified | 21 (25%, 100% after 2012) |
Lines (1–5) | 1st Line | 2nd Line | 3rd Line | 4th Line | 5th Line | Patients (n) |
---|---|---|---|---|---|---|
1 | 2-CdA | 42 | ||||
IFN-α | 24 | |||||
Splenectomy | 7 | |||||
2 | 2-CdA | 2-CdA | 8 | |||
2-CdA | 2-CdA + R | 1 | ||||
IFN-α | 2-CdA | 11 | ||||
IFN-α | IFN-α | 9 | ||||
IFN-α | Pentostatin | 2 | ||||
Splenectomy | IFN-α | 6 | ||||
Splenectomy | Chlorambucil | 1 | ||||
3 | 2-CdA | 2-CdA | 2-CdA + R | 1 | ||
IFN-α | 2-CdA | 2-CdA | 5 | |||
IFN-α | IFN-α | IFN-α | 4 | |||
IFN-α | IFN-α | 2-CdA | 3 | |||
Splenectomy | IFN-α | Pentostatin | 3 | |||
Splenectomy | IFN-α | IFN-α | 2 | |||
Splenectomy | IFN-α | 2-CdA | 1 | |||
Splenectomy | Chlorambucil | IFN-α | 1 | |||
4 | IFN-α | IFN-α | IFN-α | 2-CdA | 2 | |
IFN-α | IFN-α | IFN-α | IFN-α | 1 | ||
IFN-α | IFN-α | 2-CdA | 2-CdA | 1 | ||
IFN-α | 2-CdA | 2-CdA | 2-CdA | 1 | ||
Splenectomy | IFN-α | IFN-α | Pentostatin | 1 | ||
Splenectomy | IFN-α | Pentostatin | Pentostatin | 1 | ||
Splenectomy | IFN-α | Pentostatin | IFN-α | 1 | ||
Splenectomy | Chlorambucil | IFN-α | Pentostatin | 1 | ||
5 | IFN-α | IFN-α | IFN-α | IFN-α | IFN-α | 1 |
IFN-α | IFN-α | 2-CdA | 2-CdA | 2-CdA | 1 | |
IFN-α | 2-CdA | 2-CdA | IFN-α | 2-CdA | 1 | |
IFN-α | 2-CdA | 2-CdA | IFN-α | 2-CdA + R | 1 | |
Splenectomy | IFN-α | Pentostatin | IFN-α | 2-CdA | 1 |
Response | IFN-α | 2-CdA/Pentostatin | ||||
---|---|---|---|---|---|---|
1st Line (n = 24) | 2nd Line (n = 15) | 3rd Line (n = 7) | 1st Line (n = 42) | 2nd Line (n = 20) | 3rd Line (n = 12) | |
ORR (%) | 87.5 | 80.0 | 57.2 | 100 | 100 | 91.5 |
CRu (%) | 20.8 | 13.3 | 14.3 | 85.7 | 90 | 41.5 |
PR (%) | 66.7 | 66.7 | 42.9 | 14.3 | 10 | 50 |
NR (%) | 12.5 | - | - | - | - | 8.3 |
Patient Characteristics | 2-CdA (n = 42) | IFN-α (n = 24) | p-Value |
---|---|---|---|
Median age at diagnosis, years (range) | 53.5 (30–84) | 53.5 (25–74) | 0.61 |
Females (%) | 9 (21) | 1 (4) | 0.08 |
Follow-up (months), median (range) | 152 (1–347) | 220 (25–408) | 0.01 |
Splenomegaly, n (%) | 31 (75) | 24 (56) | 0.44 |
Longitudinal spleen diameter in ultrasound, cm (range) | 16 (12–30) | 17 (16–29) | 0.36 |
Neutrophil count (×109/L), median (range) | 0.8 (0.1–1.4) | not evaluable | not applicable |
Hemoglobin (g/L), median (range) | 119 (59–170) | 96.5 (54–128) | 0.08 |
Platelet count (×109/L), median (range) | 75 (19–328) | 73 (58–303) | 0.83 |
Any cytopenia, n (%) | 35 (83) | 19 (79) | 0.30 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bohn, J.-P.; Neururer, S.; Pirklbauer, M.; Pircher, A.; Wolf, D. Hairy Cell Leukemia Patients Have a Normal Life Expectancy—A 35-Year Single-Center Experience and Comparison with the General Population. Cancers 2022, 14, 1242. https://doi.org/10.3390/cancers14051242
Bohn J-P, Neururer S, Pirklbauer M, Pircher A, Wolf D. Hairy Cell Leukemia Patients Have a Normal Life Expectancy—A 35-Year Single-Center Experience and Comparison with the General Population. Cancers. 2022; 14(5):1242. https://doi.org/10.3390/cancers14051242
Chicago/Turabian StyleBohn, Jan-Paul, Sabrina Neururer, Markus Pirklbauer, Andreas Pircher, and Dominik Wolf. 2022. "Hairy Cell Leukemia Patients Have a Normal Life Expectancy—A 35-Year Single-Center Experience and Comparison with the General Population" Cancers 14, no. 5: 1242. https://doi.org/10.3390/cancers14051242